Fotona d.o.o., Japan.
Dr Okui's Urogynecology and Urology Clinic, Kanagawa, Japan.
Climacteric. 2020;23(sup1):S14-S17. doi: 10.1080/13697137.2019.1703940.
There are no established treatments for treating interstitial cystitis/bladder pain syndrome (IC/BPS). We conducted a study to verify the effectiveness of non-ablative vaginal erbium:YAG laser (VEL) treatment for patients with IC/BPS who were resistant to conventional treatments. A total of 12 patients without improvement after several treatments before 2016 underwent VEL treatment once a month for 12 months as per their convenience. The numeric rating scale-11 (NRS-11), O'Leary-Sant interstitial cystitis symptom and problem indexes (ICSI and ICPI), functional bladder capacity, and daily urinary frequency were obtained. In total, nine patients responded to the treatment and three did not. The NRS-11 scores and ICSI and ICPI improved in all responders. The bladder capacity and urinary frequency also normalized. The residual effect lasted for 18 months from the first treatment without long-term side-effects. VEL treatment is a safe and effective treatment in patients with IC/BPS.
目前尚无治疗间质性膀胱炎/膀胱疼痛综合征（IC/BPS）的既定方法。我们开展了一项研究，以验证非消融性阴道铒：YAG 激光（VEL）治疗对常规治疗无效的 IC/BPS 患者的有效性。2016 年之前，共有 12 名患者在经过数次治疗后未见改善，他们根据自己的方便每月接受一次 VEL 治疗，共进行 12 个月。采用数字评分量表-11（NRS-11）、O'Leary-Sant 间质性膀胱炎症状和问题指数（ICSI 和 ICPI）、膀胱功能容量和每日排尿频率来评估疗效。共有 9 名患者对治疗有反应，3 名患者无反应。所有有反应者的 NRS-11 评分和 ICSI 和 ICPI 均得到改善。膀胱容量和排尿频率也恢复正常。首次治疗后 18 个月内持续产生残余效应，且无长期副作用。VEL 治疗是一种安全有效的治疗方法，适用于 IC/BPS 患者。
